2025 · Regular session · Senate bill
SB269
SB269 requires physicians to report specified serious adverse events after certain vaccines or drugs.
Official caption: Relating to required reports of certain vaccine-related or drug-related adverse events.
Official report lists Senate author(s): Perry. This does not identify sponsors or amendment drafters.
Bill explanation published · Version and amendment review scope is stated below · Individual amendment records may not be separately annotated.
Bill highlights
Selected points from the published explanation. Follow each point to its source-linked context; conditions and limits may matter.
- SB269 requires physicians to report specified serious adverse events after certain vaccines or drugs.
- The physician must diagnose the patient with a condition related to the serious adverse event, know the patient received or used a covered product, and the event must occur before the first anniversary of vaccination or drug administration/use.
- Serious events include death, a life-threatening event, inpatient hospitalization or an extended hospital stay, persistent or significant incapacity or substantial disruption of normal life functions, a birth defect, or a medically important condition that in the physician’s reasonable judgment may require intervention to prevent those outcomes.
- For an initial violation, the Texas Medical Board uses non-disciplinary corrective action; subsequent violations are subject to discipline under the physician-regulation framework.
- A report is not proof that a product caused the event: The statutory trigger does not require the physician to establish that the vaccine or drug caused the condition.
What does it do?
SB269 requires physicians to report specified serious adverse events after certain vaccines or drugs. Its new duties cover products that are experimental or investigational, or “authorized or approved for emergency use” by the FDA. Vaccines or drugs administered or used as part of a clinical trial are excluded from these state provisions. Signed June 20, 2025, the law took effect September 1, 2025. Final law; Official history.
The physician must diagnose the patient with a condition related to the serious adverse event, know the patient received or used a covered product, and the event must occur before the first anniversary of vaccination or drug administration/use. The law does not limit the duty to the physician who administered the product. The one-year provision is the event-occurrence window, not a statement that a physician has a year to file the report.
Serious events include death, a life-threatening event, inpatient hospitalization or an extended hospital stay, persistent or significant incapacity or substantial disruption of normal life functions, a birth defect, or a medically important condition that in the physician’s reasonable judgment may require intervention to prevent those outcomes. Vaccine reports go to VAERS; drug reports go through FDA’s MedWatch. Definitions and reporting conditions; FDA reporting-program overview.
For an initial violation, the Texas Medical Board uses non-disciplinary corrective action; subsequent violations are subject to discipline under the physician-regulation framework. The board may not consider a violation for these actions after its third anniversary, but must keep the violation information in the physician’s permanent record. The health commission must adopt implementing rules. The law does not prescribe automatic license revocation for a missed report.
A report is not proof that a product caused the event. The statutory trigger does not require the physician to establish that the vaccine or drug caused the condition. The federal VAERS description expressly says the system is not designed to determine causation; it helps detect patterns needing further investigation. This briefing describes reporting duties, not a finding that a particular vaccine or drug is unsafe. Official VAERS explanation.
What changed along the way?
The original bill and both committee versions already contained the restricted product scope, clinical-trial exception, one-year event window and escalating enforcement. Of the two indexed House amendments, Frank’s amendment 1 was adopted May 21 and reversed the wording from “approved or authorized” to “authorized or approved” in both product provisions. That wording appears in the final law. Text versions; Adopted amendment.
Tinderholt’s amendment 2 would have expanded the vaccine provision to include vaccines recommended by the CDC’s Advisory Committee on Immunization Practices. It was withdrawn, not adopted. That broader category is not in the final law. The Senate concurred in the House amendment May 26. Withdrawn proposal; Amendments and dispositions; Enrolled text.
For the full amendment record, open the official amendment index.
Official bill versions
Compare the published text versions in the official text index. A change is not attributed to a specific amendment here without a verified record.
Who could benefit—and who could bear the costs?
The final posted fiscal note, May 22, 2025, anticipates no significant state fiscal impact, assumes costs can be absorbed with existing resources, and anticipates no local fiscal impact. The April 7, May 1 and other May 22 posting reach the same assessment. It does not estimate physicians’ reporting time or guarantee improved health outcomes. Final fiscal note.
Patients and safety-monitoring programs may benefit from additional information about serious events; physicians face record-review and reporting duties and possible corrective or disciplinary action. The clinical-trial exclusion narrows this state mandate, not all federal reporting requirements. More reports alone would not establish that a product causes more injuries. Scope and enforcement; How VAERS data are used.
Official sources
- Bill history and latest recorded action
- Bill versions, analyses and fiscal notes
- Action history and votes
- Amendment index
Catalog report retrieved 2026-10-25. Check the official record for corrections or later changes.
